Gyre Therapeutics (GYRE) Capital Expenditures (2010 - 2026)
Gyre Therapeutics (GYRE) reported Capital Expenditures of $178000.0 for Q1 2026, up 45.9% year-over-year from $122000.0 in Q1 2025, and up 23.61% quarter-over-quarter from $144000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Capital Expenditures (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 15 years of Capital Expenditures data on file, last reported at $178000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $178000.0, up 45.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 43.52% YoY), and the FY2025 annual result was $1.2 million, down 48.6% from the prior year.
- Capital Expenditures advanced to $178000.0 in Q1 2026 per GYRE's latest filing, from $144000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $2.5 million in Q2 2023 and troughed at -$65000.0 in Q4 2024.
- A 4-year average of $938461.5 and a median of $668000.0 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures sank 102.8% in 2024, then surged 321.54% in 2025.
- A 4-year view of Capital Expenditures shows it stood at $2.3 million in 2023, then slumped by 102.8% to -$65000.0 in 2024, then surged by 321.54% to $144000.0 in 2025, then climbed by 23.61% to $178000.0 in 2026.
- Business Quant data shows GYRE's Capital Expenditures at $178000.0 in Q1 2026, $144000.0 in Q4 2025, and $668000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | 178,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 178,000.00 |
| Mar 31, 2026 | 178,000.00 |
| Dec 31, 2025 | 144,000.00 |
| Dec 31, 2025 | 144,000.00 |
| Sep 30, 2025 | 668,000.00 |
| Sep 30, 2025 | 668,000.00 |
| Jun 30, 2025 | 256,000.00 |
| Jun 30, 2025 | 256,000.00 |
| Mar 31, 2025 | 122,000.00 |
| Mar 31, 2025 | 122,000.00 |
| Dec 31, 2024 | -65,000.00 |
| Dec 31, 2024 | -65,000.00 |
| Sep 30, 2024 | 693,000.00 |
| Sep 30, 2024 | 693,000.00 |
| Jun 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Mar 31, 2024 | 231,000.00 |
| Mar 31, 2024 | 231,000.00 |
| Dec 31, 2023 | 2.32 Mn |
| Dec 31, 2023 | 2.32 Mn |